Astonea Labs Reports 147% Surge in H1 Net Profit to ₹4.7 Crore as Margins Expand

Key numbers

1-Year Price Change	151.35%Outperforming
Market Cap	₹367.88 CrMicro Cap
P/E Ratio	81.47Sector PE 43.77
Promoter Holding	72.44%Latest Quarter

Key highlights

• Net profit increased 147.4% YoY to ₹4.7 crore in H1-27 from ₹1.9 crore in H1-26
• Revenue from operations grew 44.6% to ₹95.9 crore compared to ₹66.3 crore in the year-ago period
• Operating margins expanded to 7.5% from 2.3% following a 1,086 bps improvement in gross margins
• Company recorded an exceptional loss of ₹0.46 crore due to a fire incident at the plant in April 2026
• Board approved a proposal to subscribe to 51% share capital of Longevity Science Private Limited
• Exports network expanded to nine markets across Central and South America and the Caribbean

OTC Brands and Global Exports Drive Revenue Growth

Astonea Labs reported revenue from operations of ₹95.9 crore for H1-27, a 44.6% increase over the ₹66.3 crore recorded in the same period last year. Management attributed the growth to a higher share of sales coming from the company's own OTC brand portfolio, including the newly launched anti-ageing cream Young Fuel. The company's export network now spans nine markets after appointing distributors in Guatemala and Panama.

Operational efficiency also improved as tablet output capacity rose by 35%, and the manufacturing plant attained compliance with revised Schedule M and WHO-GMP standards.

Margin Expansion Despite Operational Headwinds

• Operating margins climbed to 7.5% in H1-27, a sharp rise from 2.3% in H1-26
• Gross margins reached 37.6%, compared to 26.7% in the previous year's first half
• Exceptional loss of ₹0.46 crore was recognized following a fire at the plant on April 27, 2026
• Five regulatory audits in September 2026 temporarily slowed plant operations
• Inventory levels rose to 83 days as some dispatches were pushed into the third quarter
• Receivable days showed improvement, falling to 101 from 146 in September 2025

Strategic Acquisition and FY27 Outlook

For FY27 we target revenue of ₹215 crore or more, an EBITDA margin of 13–15% and a PAT margin of 5–6%. Our H1 FY27 margins of 13.8% and 5.0% are already within these ranges.

Balance Sheet Strength and New Ventures

The company’s net worth stood at ₹72.19 crore as of September 30, 2026, with gross borrowings at ₹57.15 crore. The Board has approved a proposal to acquire a 51% stake in Longevity Science Private Limited, a recently incorporated entity, which will become a subsidiary of Astonea Labs upon completion of formalities. The company also confirmed it has filed 95 dossiers for product registrations across Nicaragua, Bolivia, Guatemala, and Panama.

Net working capital stood at 107 days, down from 150 days a year ago, reflecting tighter capital management.

What to watch next

• Completion of the 51% share capital subscription in Longevity Science Private Limited
• Finalization of insurance claims for the plant fire incident that occurred in April 2026
• Expected product registrations in Ghana, Ethiopia, and Kenya following plant inspections
• Execution of Q3 dispatches that were deferred due to September regulatory audits

“H1 FY27 was our best half so far. Revenue from operations grew 44.6% YoY to ₹95.86 crore, and 17.9% HoH over H2 FY26. EBITDA rose 140.7% YoY to ₹13.20 crore and profit after tax rose 153.3% YoY to ₹4.82 crore.”

Astonea Labs · financial snapshot

Share price	₹350
Market capitalisation	₹367.88 Cr
Revenue (annual)	₹147.58 Cr
Net profit (annual)	₹4.52 Cr
P/E (TTM)	81.47×Sector 43.74×
Promoter holding	72.44%
FII holding	0%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.